Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer’s Disease (original) (raw)
Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000; 54 Suppl. 5: S4–9 PubMedCAS Google Scholar
Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. Neurology 1999; 52: 78–84 ArticlePubMedCAS Google Scholar
McKahnn G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44 Article Google Scholar
Selkoe DJ. Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann N Y Acad Sci 2000; 924: 7–25 Google Scholar
McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Let 1987; 79: 195–200 ArticleCAS Google Scholar
Willard LB, Hauss-Wegrzyniak B, Danysz W, et al. The cytotoxicity of chronic neuroinflammation upon basel fore-brain cholineric neurons of rats can be attenuated by glutamatergic antagoinsim or cyclooxygenase-2 inhibition. Exp Brain Res 2000; 134: 58–65 ArticlePubMedCAS Google Scholar
Hensley K, Robinson KA, Gabbita SP, et al. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28: 1456–62 ArticlePubMedCAS Google Scholar
McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer’s disease. Neurobiol Aging 2001; 22: 799–809 ArticlePubMedCAS Google Scholar
Nicoll JA, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 2000; 47: 365–8 ArticlePubMedCAS Google Scholar
Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiology 1992; 263 (1 Pt 1): C1–C16 CAS Google Scholar
Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997; 388: 878–81 ArticlePubMedCAS Google Scholar
Blasko I, Marx F, Steiner E, et al. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the production of APPs. FASEB J 1999; 13: 63–8 PubMedCAS Google Scholar
Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 8; 400(6740): 173–7 ArticlePubMedCAS Google Scholar
Poduslo JF, Curran GL. Amyloid β peptide as a vaccine for Alzheimer’s disease involves receptor-mediated transport at the blood-brian barrier. Neuroreport 2001; 12: 3197–200 ArticlePubMedCAS Google Scholar
Koistinaho M, Kettunen MI, Goldsteins G, et al. β-amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A 2002; 99: 1610–5 ArticlePubMedCAS Google Scholar
Yermakova AV, Rollins J, Callahan LM, et al. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58: 1135–46 ArticlePubMedCAS Google Scholar
Hoozemans JJ, Rozemuller AJ, Janssen I, et al. Cyclooxygenase expression in microglia and neurons in Alzheimer’s disease and control brain. Acta Neuropathol (Berl) 2001; 101: 2–8 CAS Google Scholar
Delves PJ, Roitt IM, editors. Encyclopedia of immunology. 2nd ed. New York: Academic Press, 1998 Google Scholar
Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999; 155: 995–1004 ArticlePubMedCAS Google Scholar
Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391: 281–5 ArticlePubMedCAS Google Scholar
Fiebich BL, Lieb K, Hull M, et al. Effects of NSAIDs on IL-1β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport 1996; 7: 1209–13 ArticlePubMedCAS Google Scholar
Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000; 20: 5709–14 PubMedCAS Google Scholar
Blasko I, Apochal A, Boeck G, et al. Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis 2001; 8: 1094–101 ArticlePubMedCAS Google Scholar
Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidgenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414: 212–6 ArticlePubMedCAS Google Scholar
Oviedo JA, Wolfe MM. Clinical potential of cyclo-oxygenase-2 inhibitors. BioDrugs 2001; 15: 563–72 ArticlePubMedCAS Google Scholar
Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, et al. Neurochem neuroprotective effects of non-steroidal antiinflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001; 76: 1895–904 ArticlePubMedCAS Google Scholar
Jaradat MS, Wongsud B, Phornchirasilp S, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587–95 ArticlePubMedCAS Google Scholar
Fenner H. Comparative biochemical pharmacology of the oxicams. Scand J Rheumatol Suppl 1987; 65: 97–101 ArticlePubMedCAS Google Scholar
De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer’s disease and multi-infarct dementia. Mech Ageing Dev 2001; 122: 1985–95 ArticlePubMed Google Scholar
Monsonego A, Maron R, Zota V, et al. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001; 98: 10273–8 ArticlePubMedCAS Google Scholar
Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol 2002; 52: 168–74 ArticlePubMed Google Scholar
Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer’s disease in Australia. Neurology 1990; 40: 1698–707 ArticlePubMedCAS Google Scholar
French LR, Schuman LM, Mortimer JA, et al. A case-control study of dementia of the Alzheimer’s type. Am J Epidemiol 1985; 121: 414–21 PubMedCAS Google Scholar
Heyman A, Wilkinson WE, Stafford JA, et al. Alzheimer’s disease: a study of epidemiological aspects. Ann Neurology 1984; 15: 335–41 ArticleCAS Google Scholar
Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer’s disease. Ann Neurol 1990; 28: 766–74 ArticlePubMedCAS Google Scholar
Myllykangas-Luosujarvi R, Isomaki H. Alzheimer’s disease and rheumatoid arthritis [letter]. Br J Rheumatol 1994; 33: 501–2 ArticlePubMedCAS Google Scholar
Henderson AS, Jorm AF, Korten AE, et al. Environmental risk factors for Alzheimer’s disease: their relationship to age of onset and to familial or sporadic types. Psychol Med 1992; 22: 429–36 ArticlePubMedCAS Google Scholar
Amaducci LA, Fratiglioni F, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer’s disease: a case-control study of an Italian population. Neurology 1986; 36: 922–31 ArticlePubMedCAS Google Scholar
Kukull WA, Larson EB, Stergachis A, et al. Nonsteroidal antiinflammtory drug use and risk of Alzheimer’s disease [abstract]. Neurology 1994; 44 Suppl. 2: A237 Google Scholar
Breitner JC, Gau BA, Welsh KA, et al. Inverse association of antiinflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44: 227–32 ArticlePubMedCAS Google Scholar
Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer’s disease with nonsteroidal antiinflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523–30 ArticlePubMedCAS Google Scholar
Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000; 54: 2066–71 ArticlePubMedCAS Google Scholar
Canadian Study of Health and Aging. The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–80 Article Google Scholar
Beard CM, Waring SC, O’Brien PC, et al. Nonsteroidal antiinflammatory drug use and Alzheimer’s disease: a case control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998; 73: 951–5 ArticlePubMedCAS Google Scholar
Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 1995; 45: 441–5 Article Google Scholar
Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research methods. New York: Van Nostrand Reinhold Company, 1982 Google Scholar
Lasky T, Stolley PD. Selection of cases and control. Epidemiol Rev 1994; 16: 6–17 PubMedCAS Google Scholar
Hoes AW, Grobbee DE, Lubsen J. Primary prevention in hypertension: valid conclusions from observational studies. Circulation 1991; 84 (6 Suppl.): VI78–83 PubMedCAS Google Scholar
Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48: 626–32 ArticlePubMedCAS Google Scholar
In’t Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345: 1515–21 Article Google Scholar
Sainaili SM, Ingram DM, Talwaker S. Results of a double-blind placebo controlled study of celecoxib for the progression of Alzheimer’s disease. 6th International Stockholm-Springfield Symposium in Alzheimer’s Disease Therapy; 2000 Apr 5–8; Stockholm
Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology 2002; 58: 1050–4 ArticlePubMedCAS Google Scholar
Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54: 588–93 CAS Google Scholar
Scharf S, Mander A, Ugoni A, et al. A double-blind, placebocontrolled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53: 197–201 ArticlePubMedCAS Google Scholar
Van Gool WA, Weinstein HC, Scheltens P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358: 455–60 ArticlePubMed Google Scholar
Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer’s disease. J Pain Symptom Manage 2002; 23 (4 Suppl.): S35–40 ArticlePubMedCAS Google Scholar
Martin BK, Meinert CL, Breitner JC, et al. Double placebo design in a prevention trial for Alzheimer’s disease. Control Clin Trials 2002; 23: 93–9 ArticlePubMed Google Scholar